Hemasphere

Papers
(The H4-Index of Hemasphere is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal127
Abstract Book: 25th Congress of the European Hematology Association Virtual Edition, 202064
Hypoferremia is Associated With Increased Hospitalization and Oxygen Demand in COVID‐19 Patients52
EHA2021 Virtual Congress Abstract Book51
2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia49
JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives47
Azacytidine Treatment for VEXAS Syndrome47
Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study46
Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments45
Hemophilia Gene Therapy: Approaching the First Licensed Product40
Chronic Myeloid Leukemia in 202040
Longitudinal Cytokine Profiling Identifies GRO‐α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia38
The Emerging Role of Convalescent Plasma in the Treatment of COVID‐1937
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow‐up Samples From Four Prospective Trials of the European MCL Network36
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party34
COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma33
SARS-CoV-2 Vaccines in Patients With Multiple Myeloma30
EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer29
EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-1929
Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma28
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies28
Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management27
Treatment for Relapsed/Refractory Acute Myeloid Leukemia25
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)25
Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results24
Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms24
0.057154178619385